TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
GlobeNewswire - Wed Dec 17, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the appointment of Kenneth Hoberman to the Company's Board of Directors. Mr. Hoberman is currently the Chief Operating Officer of Stemline Therapeutics, Inc. (Nasdaq:STML), a publicly-traded biotechnology company and was formerly the VP, Corporate and Business Development of Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a publicly-traded biotechnology company.
TGTX: 16.03 (+0.33), STML: 15.53 (+0.23), KERX: 14.00 (+0.20)
Stemline Therapeutics Initiates SL-401 Clinical Trial in Four Rare Myeloproliferative Neoplasms
GlobeNewswire - Tue Dec 16, 9:35AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the initiation of a clinical trial with SL-401 in four rare myeloproliferative neoplasms (MPN). SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of a wide range of hematologic cancers. This represents the third clinical trial with SL-401, across seven oncologic indications, that Stemline has opened in the second half of 2014.
STML: 15.53 (+0.23)
Why You Shouldn't Bet Against Stemline Therapeutics (STML) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 7:39AM CST
Stemline Therapeutics is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 57
STML: 15.53 (+0.23)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 1.63 (-0.04), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), ONTX: 3.82 (+0.06), CTIC: 2.36 (+0.05), BMY: 59.15 (-0.01), STML: 15.53 (+0.23), NVS: 93.91 (+0.66), MEIP: 3.90 (+0.11), CELGZ: 3.34 (-0.01), XLRN: 38.80 (+0.80)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 71.57 (+1.99), AZN: 70.44 (+0.26), AMGN: 160.67 (+3.15), ONTX: 3.82 (+0.06), GSK: 42.85 (+0.11), STML: 15.53 (+0.23)
Stemline Therapeutics Announces Multiple Preclinical Presentations Highlighting Its Pipeline of IL-3R-Directed Therapeutics at the American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Fri Dec 05, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that results from multiple ongoing preclinical studies were selected for presentation at the 2014 American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2014 at the Moscone Center, San Francisco, CA. Investigators will present data on Stemline's portfolio of therapeutics that target the interleukin-3 receptor (IL-3R), which is overexpressed on tumor bulk and cancer stem cells (CSCs) of a wide variety of hematologic malignancies.
STML: 15.53 (+0.23)
Stemline Therapeutics beats 3Q profit forecasts
Automated Insights - Wed Nov 12, 9:15AM CST
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Wednesday reported a third-quarter loss of $6.9 million.
STML: 15.53 (+0.23)
Stemline Therapeutics beats by $0.05
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:35AM CST
STML: 15.53 (+0.23)
Stemline Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Wed Nov 12, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended September 30, 2014 and provided a corporate update.
STML: 15.53 (+0.23)
Stemline Therapeutics to Participate in the Barclays Select Series Symposium
GlobeNewswire - Mon Nov 10, 6:07AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Stemline will participate in the Barclays Select Series Symposium taking place November 12-13, 2014. The symposium will take place at Barclays' offices in New York, NY, and "will bring together a diverse group of Small & Mid Cap companies that hold strong investment appeal based on their fundamental prospects."
STML: 15.53 (+0.23)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014
M2 - Thu Nov 06, 3:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/7vhcvg/chronic) has announced the addition of the "Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Piramal Enterprises Limited - Nanotherapeutics, Inc. - Bio-Path Holdings, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Incyte Corporation - Ariad Pharmaceuticals, Inc. - JW Pharmaceutical Corporation - Ilyang Pharmaceutical Co., Ltd - Jiangsu Hengrui Medicine Co., Ltd. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Natco Pharma Limited - Hybrigenics S.A. - SymBio Pharmaceuticals Limited - Nerviano Medical Sciences - Constellation Pharmaceuticals, Inc. - Deciphera Pharmaceuticals, LLC - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Mirna Therapeutics, Inc. - KaloBios Pharmaceuticals, Inc. - AB Science For more information visit http://www.researchandmarkets.com/research/7vhcvg/chronic
PFE: 31.42 (-0.03), INCY: 71.57 (+1.99), ONTX: 3.82 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), STML: 15.53 (+0.23), SNTA: 2.63 (+0.02), KBIO: 1.63 (-0.04), BPTH: 2.80 (+0.03), CELGZ: 3.34 (-0.01), NVS: 93.91 (+0.66)
Stemline Therapeutics Initiates SL-401 Trial in AML Patients in First Complete Response With Minimal Residual Disease, the Second SL-401 Trial Initiated in 2H14
GlobeNewswire - Thu Oct 16, 6:05AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the initiation of its second clinical trial for SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of a wide range of hematologic cancers. This trial will enroll patients with acute myeloid leukemia (AML) who have achieved a complete response (CR) following their first course of induction chemotherapy, but display evidence of minimal residual disease (MRD) in their bone marrow and are at high risk for relapse. The study is designed to enroll at least 33 patients and will include a brief lead-in that will transition into a larger expansion stage. The trial will evaluate, among other parameters, SL-401's ability to eradicate evidence of MRD and increase CR duration. Participating sites include MD Anderson Cancer Center (Houston, TX), Duke University Medical Center (Durham, NC), and other major centers. This trial follows the first trial of SL-401, which is in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory AML and is actively accruing patients.
STML: 15.53 (+0.23)
Brain Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnncfl/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Neuralstem, Inc. - Bionomics Limited - Critical Outcome Technologies Inc. - Prana Biotechnology Limited - e-Therapeutics plc - AngioChem Inc. - Merrimack Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Kinex Pharmaceuticals, LLC - Nuvilex, Inc. - TAU Therapeutics, LLC - CureFAKtor Pharmaceuticals. LLC - Arrien Pharmaceuticals, LLC - Oncology Research International Limited For more information visit http://www.researchandmarkets.com/research/nn...ain_cancer
MACK: 10.91 (+0.36), STML: 15.53 (+0.23), PRAN: 1.74 (-0.02), CUR: 2.70 (+0.07)
Can The Uptrend Continue for Stemline Therapeutics (STML)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:46AM CDT
Can The Uptrend Continue for Stemline Therapeutics (STML)?
STML: 15.53 (+0.23)
Nasdaq stocks posting largest percentage decreases
AP - Fri Sep 12, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
TRNS: 9.80 (-0.10), EFOI: 5.10 (+0.01), EOPN: 9.37 (-0.02), AKAO: 12.76 (-0.23), TIPT: 7.94 (+0.14), HCCI: 11.76 (-0.41), ISNS: 2.77 (+0.04), MNDL: 3.22 (+0.08), STML: 15.53 (+0.23), OREX: 5.98 (+0.01), CROX: 12.37 (+0.04), ECYT: 6.33 (+0.24), SCYX: 10.49 (+0.65), FLXS: 32.00 (-0.18), PEIX: 11.15 (+0.37)
Surging Earnings Estimates Signal Good News for Stemline Therapeutics (STML) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:37AM CDT
Positive earnings estimate revisions suggest that analysts are becoming more optimistic on Stemline Therapeutics’s earnings for the coming quarter and year.
STML: 15.53 (+0.23)
T-Cell Leukemia Therapeutics Pipeline Review 2014 - 15 Drug Profiles from 10 Leading Pharma Companies
M2 - Wed Sep 10, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shcdvv/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Sanofi - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - Applied Immune Technologies Ltd Drug Profiles - alemtuzumab - mogamulizumab - lenalidomide - PF-03084014 - BMS-906024 - PCI-34051 - NK-314 - Recombinant Protein for CNS, Oncology, Hematological Disorders and Metabolic Disorders - Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease - MMIG-202 - INA-01 - SL-101 - Antibody Targeting HLA-A2 for Neurology, Infectious Diseases and Oncology - Synthetic Peptide for Oncology and Male health - Cell Therapy to Target CD38 for cancer For more information visit http://www.researchandmarkets.com/research/sh...l_leukemia
PCYC: 121.84 (+1.15), PFE: 31.42 (-0.03), BMY: 59.15 (-0.01), STML: 15.53 (+0.23), CELGZ: 3.34 (-0.01)
Stemline Therapeutics (STML) in Focus: Stock Up 12.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:51AM CDT
Stemline Therapeutics, Inc. (STML) was a big mover last session, as its shares rose over 12% on the day.
CBPO: 64.79 (-0.59), CBM: 21.62 (+0.37), GILD: 91.29 (+1.84), STML: 15.53 (+0.23)
Is Stemline Therapeutics (STML) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:41AM CDT
Stemline Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
STML: 15.53 (+0.23)